BioLine Rx (XTAE:BLRX) FCF Yield % : -40.84 (As of May. 01, 2024)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, BioLine Rx's Trailing 12-Month Free Cash Flow is ₪-85.53 Mil, and Market Cap is ₪211.04 Mil. Therefore, BioLine Rx's FCF Yield % for today is -40.84%.

The historical rank and industry rank for BioLine Rx's FCF Yield % or its related term are showing as below:

XTAE:BLRX' s FCF Yield % Range Over the Past 10 Years
Min: -47.69 Med: -27 Max: -20.96
Current: -40.84

During the past 13 years, the highest FCF Yield % of BioLine Rx was -20.96%. The lowest was -47.69%. And the median was -27.00%.

XTAE:BLRX's FCF Yield % is ranked worse than
71.07% of 1552 companies
in the Biotechnology industry
Industry Median: -14.81 vs XTAE:BLRX: -40.84

BioLine Rx's FCF Margin % for the quarter that ended in Dec. 2023 was 103.61%.

BioLine Rx FCF Yield % Historical Data

The historical data trend for BioLine Rx's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx FCF Yield % Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-91.94

-45.11

-28.65

-76.86

-20.64

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-68.43	-65.35	-40.13	-31.57	17.92

Competitive Comparison of BioLine Rx's FCF Yield %

For the Biotechnology subindustry, BioLine Rx's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's FCF Yield % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's FCF Yield % falls into.

BioLine Rx FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

BioLine Rx's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-85.657	/	415.07738
	=	-20.64%

BioLine Rx's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	18.598	*	4	/	415.07738
	=	17.92%

BioLine Rx FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

BioLine Rx FCF Yield % Related Terms

Thank you for viewing the detailed overview of BioLine Rx's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.